> Redx Pharma got approval to restart a phase 1/2a trial of its oral porcupine inhibitor RXC004. The trial has been on hold since the first person dosed suffered significant adverse events in March, forcing Redx to halt the study and lower the starting dose. Statement
> BerGenBio began a phase 1 trial of its anti-AXL antibody-drug conjugate ADCT-601. The Norwegian biotech is assessing the drug in patients with advanced solid tumors. Release
> Achilles Therapeutics secured clearance to run a phase 1/2 trial of its tumor-derived T cell therapy in patients with advanced non-small cell lung cancer. The study is set to start enrolling patients in the second half of the year. Statement
> San Raffaele-Telethon Institute for Gene Therapy published clinical data on Orchard Therapeutics’ beta-thalassemia gene therapy OTL-300. Release
> ObsEva shared initial safety data on its treatment for preterm labor. The drug, OBE022, was well tolerated by the mothers and fetuses. Statement
> Basilea Pharmaceutica struck a deal with its compatriot Roche to test derazantinib in combination with checkpoint inhibitor Tecentriq. A phase 1/2 trial of the combination is due to start around the middle of the year. Release